Advertisement

Evaluation of Cytochrome P450 Inhibition in Human Liver Microsomes

  • Zhengyin Yan
  • Gary W. Caldwell
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

Evaluation of lead compounds for P450 inhibition in human liver microsomes has been widely accepted as an in vitro approach to assess drug interaction potential. This chapter describes a detailed traditional CYP inhibition protocol for six major isoforms: 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4. Microsomal incubation conditions were optimized and kinetic parameters determined to initially establish the inhibition assay. In CYP inhibition assay, separated incubations were performed for individual CYPs, and resulting samples were pooled and analyzed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). It is without doubt that results from this in vitro experiment are of great value in lead optimization in drug discovery and development. It is obvious that more efforts are still needed to establish the relevance between in vitro CYP inhibition and drug interactions in the clinic.

Key Words

CYPs drug interactions P450 inhibition 

References

  1. 1.
    Yan, Z. and Caldwell, G. W. (2001) Metabolism profiling, and cytochrome P450 inhibition and induction in drug discovery. Curr. Top. Med. Chem. 1, 403–425.PubMedCrossRefGoogle Scholar
  2. 2.
    Crespi, C. L. and Stresser, D. M. (2001) Fluorometric screening for metabolismbased drug-drug interactions. J. Pharm. Toxicol. Methods 44, 325–331.CrossRefGoogle Scholar
  3. 3.
    Chu, I., Favreau, L., Soares, T., Lin, C. C., and Nomeir, A. A. (2000) Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Comm. Mass Spectr. 14, 207–214.CrossRefGoogle Scholar
  4. 4.
    Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., and Lin, J. H. (2002) Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30, 1280–1287.PubMedCrossRefGoogle Scholar
  5. 5.
    Yuan, R., Madani, S., Wei, X. X., Reynolds, K., and Huang, S. M. (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 30, 1311–1319.PubMedCrossRefGoogle Scholar
  6. 6.
    Dierks, E. A., Stams, K. R., Lim, H.-K., Cornelius, G., Zhang, H., and Ball, S. E. (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 29, 23–29.PubMedGoogle Scholar
  7. 7.
    Peng, S. X., Barbone, A. G., and Ritchie, D. M. (2003) High-throughput cytochrome P450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns. Rapid Comm. Mass Spectr. 17, 509–518.CrossRefGoogle Scholar
  8. 8.
    Bu, H. Z., Knuth, K., Magis, L., and Teitelbaum, P. (2000) High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy: IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Comm. Mass Spectr. 14, 1943–1948.CrossRefGoogle Scholar
  9. 9.
    Yin, H., Racha, J., Li, S. Y., Olejnik, N., Saton, H., and Moore, D. (2000) Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica 30, 141–154.PubMedCrossRefGoogle Scholar
  10. 10.
    Tucker, G. T., Houston, J. B., and Huang, S. M. (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm. Res. 18, 1071–1080.PubMedCrossRefGoogle Scholar
  11. 11.
    Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815–832.PubMedCrossRefGoogle Scholar
  12. 12.
    Ha-Duong, N.-T., Dijols, S., Macherey, A.-C., Goldstein, J. A., Dansette, P. M., and Mansuy, D. (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40, 12,112–12,122.PubMedCrossRefGoogle Scholar
  13. 13.
    Palamanda, J. R., Casciano, C. N., Norton, L. A., Clement, R. P., Favreau, L. V., Lin, C.-C., et al. (2001) Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine. Drug Metab. Dispos. 29, 863–867.PubMedGoogle Scholar
  14. 14.
    Busby, W. F., Jr., Ackermann, J. M., and Crespi, C. L. (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of CDNA-expressed human cytochromes P-450. Drug Metab. Dispos. 27, 246–249.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2004

Authors and Affiliations

  • Zhengyin Yan
    • 1
  • Gary W. Caldwell
    • 1
  1. 1.Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, LLCSpring House

Personalised recommendations